NRX Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for serious neuropsychiatric and pulmonary conditions. The company’s core work centers on central nervous system disorders, particularly severe bipolar depression associated with suicidal ideation, as well as life-threatening pulmonary diseases. Its lead program, NRX-101, is an investigational oral therapy targeting suicidal bipolar depression, designed as part of a sequential treatment regimen intended to address acute and sub-acute suicidal ideation and behavior. NRX Pharmaceuticals also explores non-hallucinogenic NMDA receptor–modulating approaches for conditions such as post-traumatic stress disorder, emphasizing mechanisms that avoid addiction and neurotoxicity. Operating today as a specialized developer within the biopharmaceutical sector, NRX Pharmaceuticals plays a niche role in addressing areas of high unmet medical need, particularly where current treatment options are limited or inadequate. Founded in 2017 and headquartered in Wilmington, Delaware, the company engages primarily in research, clinical development, and partnerships aimed at ultimately enabling commercialization of its pipeline candidates.